Need a Product or service?

Boehringer Ingelheim has now released the results of a series of field evaluations which have assessed the performance of the vaccine compared with competitor products. The results show that the vaccine has been performing consistently well and in most cases, better than the available alternatives.

Ingelvac M hyo utilises a unique new adjuvant system called 'Impran' that provides sustained antigen release and enhanced immune stimulation. The Boehringer Ingelheim team was keen to assess efficacy in the field to support the excellent results of previous scientific study.

One investigation was carried out on a commercial farm in Yorkshire to compare the benefits of vaccination with the farm's previous non-vaccination policy. Pigs on this farm are routinely moved off-site where they are mixed with other pigs and have, regularly in the past, suffered enzootic pneumonia and related disease.

After the slaughter check results, the team discovered that only 17% of the vaccinated batch had significant pneumonia lesions compared with 50% of the non-vaccinated pigs. The average 'lung score,' (carried out using a standard lung scoring method) had decreased to 1.8 in the vaccinated group compared with 7.2 in the non-vaccinated pigs - a significant reduction.

In another study on a unit in East Yorkshire, Ingelvac M hyo was compared to an M hyo/Glasser's disease combination vaccine which had been previously used. Using the same lung scoring method, the pigs receiving the combination vaccine had an average lung score of 5.9 compared with those that had been vaccinated with Ingelvac M hyo which were down to 2.2.

In a large outdoor herd in Hampshire, Ingelvac M hyo was introduced to replace a competitor one-dose product. Ingelvac M hyo performed equally, if not better, than the one shot competitor. It was also noted by farmers involved in the trial, that the rare reactions that have been reported following use of some M hyo vaccines were not seen when Ingelvac M hyo was used. This may be related to the prolonged and slow release of antigen facilitated by Ingelvac M hyo's unique Impran adjuvant system or due to its non-mineral oil adjuvant oil.

Manager of the Production Animal business at Boehringer Ingelheim, Allan Henderson comments, "There's just no arguing with these results and after more than a year in the market, more and more proactive farmers and vets across the country are reviewing their current practices only to decide that Ingelvac M hyo is the vaccine they want to protect their herds, and consequently, their profits."

Source: Boehringer Ingelheim Press Release - 16th June 2004